Advertisement
Clinical Therapeutics
Advanced searchSave search
Original Research| Volume 38, ISSUE 8, P1778-1788, August 2016

Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects

Published:July 27, 2016DOI:https://doi.org/10.1016/j.clinthera.2016.06.010
Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects
Previous ArticleSuperbugs, Colistin, and Related Issues
Next ArticleMedication Persistence, Duration of Treatment, and Treatment-switching Patterns Among Canadian Patients Taking Once-daily Extended-release Methylphenidate Medications for Attention-Deficit/Hyperactivity Disorder: A Population-based Retrospective Cohort Study

      Abstract

      Purpose

      The purpose of this study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of single 100 U/kg subcutaneous doses of Epoetin Hospira and Epogen in healthy male subjects as part of an overall program to demonstrate biosimilarity of Epoetin Hospira to the reference product Epogen.

      Methods

      This single-center, open-label, randomized, 2-period, crossover study was conducted in 81 healthy male subjects. Subjects were randomized to Sequence 1, in which they received 100 U/kg of Epoetin Hospira or to sequence 2, in which they received 100 U/kg Epogen subcutaneously in the first study period and the alternative treatment in the second study period. Blood was collected for determination of baseline-adjusted epoetin concentrations (BAECs) for pharmacokinetics and for determination of reticulocyte percentage of total erythrocytes for pharmacodynamics throughout both study periods. The primary PK end points were the geometric mean ratios (GMRs) of the 2 treatments for AUC0–t and Cmax based on the BAEC, and the primary PD end points were the GMRs of the 2 treatments for AUC0–t and Cmax for reticulocyte percentage.

      Findings

      The GMRs of Epoetin Hospira to Epogen for the BAEC-derived PK parameters were 1.05 for AUC0–t with a 90% CI of 1.01 to 1.11, and 1.09 for Cmax with a 90% CI of 1.01 to 1.18, with both 90% CIs contained within the prespecified equivalence margin of 0.80 to 1.25. The GMRs (Epoetin Hospira/Epogen) for the reticulocyte percentage–derived PD parameters were 1.01 for AUC0–t with a 95% CI of 0.98 to 1.05, and 1.02 for Cmax with a 95% CI of 0.98 to 1.06, with both 95% CIs contained within the prespecified equivalence margin of 0.80 to 1.25. Overall, the adverse events were of similar frequency (11.7% and 13.9% for Epoetin Hospira and Epogen, respectively) and severity between treatments. One subject had a positive anti– recombinant human erythropoietin antibody result by radioimmunoprecipitation assay before dosing and throughout the conduct of the study with negative neutralizing antibodies and with no evidence of clinical deterioration or impact on the pharmacokinetics, pharmacodynamics, or safety.

      Implications

      The results of this study established the PK and PD equivalence of single 100 U/kg subcutaneous doses of the proposed biosimilar Epoetin Hospira to the reference product Epogen in healthy male subjects and support the overall demonstration of biosimilarity of Epoetin Hospira and Epogen.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Ridley D.M.
        • Dawkins F.
        • Perlin E.
        Erythropoietin: A review.
        J Natl Med Assoc. 1994; 86: 129-135
        View in Article
        • Wang G.L.
        • Semenza G.L.
        Molecular basis of hypoxia-induced erythropoietin expression.
        Curr Opin Hematol. 1996; 3: 156-162
        View in Article
        • Lacombe C.
        • Mayeux P.
        The molecular biology of erythropoietin.
        Nephrol Dial Transplant. 1999; 14: 22-28
        View in Article

      4. Epogen® (Epoetin alfa) Package Insert. June, 2014 Amgen Inc. http://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5&type=pdf&name=1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5. Accessed February 16, 2016

        View in Article

      5. Public Health Service Act, Section 351 (42 US Code 262). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf. Accessed February 16, 2016

        View in Article

      6. FDA Draft Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. February 2012. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf. Accessed February 16, 2016

        View in Article
        • Fishbane S.
        • Shah H.H.
        The emerging role of biosimilar epoetin in nephrology in the United States.
        Am J Kidney Dis. 2015; 65: 537-542
        View in Article

      8. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. CHMP/437/04. EMEA 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Accessed July 19, 2016

        View in Article
        • Weise M.
        • Kurki P.
        • Wolff-Holz E.
        • et al.
        Biosimilars: the science of extrapolation.
        Blood. 2014; 124: 3191-3196
        View in Article

      10. European Medicines Agency, Committee for Medicinal Products for Human Use: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (EMA/CHMP/BWP/247713/2012). http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&mid=WC0b01ac058002958c. Accessed February 16, 2016

        View in Article

      11. FDA Guidance for Industry ANDA Submissions – Content and Format of Abbreviated New Drug Applications. June 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm400630.pdf. Accessed February 16, 2016

        View in Article
        • Roberts D.
        • Smith D.J.
        Erythropoietin does not demonstrate circadian rhythm in healthy men.
        J Applied Physiology. 1996; 80: 847-851
        View in Article
        • Cheung W.K.
        • Goon B.L.
        • Guilfoyle M.C.
        • Wacholtz M.C.
        Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
        Clin Pharmacol Ther. 1998; 64: 412-423
        View in Article

      14. FDA Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. January 2001. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070244.pdf. Accessed February 16, 2016

        View in Article

      15. FDA Draft Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs – General Considerations. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdf. Accessed February 16, 2016

        View in Article

      16. FDA Specific Guidance for Erythropoietin Biosimilars. http://drug.fda.moph.go.th/zone_admin/files/Specific%20Guidance%20for%20Epo%20-%20Biosimilars_01Apr.pdf. Accessed February 16, 2016

        View in Article
        • Ramakrishnan R.
        • Cheung W.K.
        • Wacholtz M.C.
        • et al.
        Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.
        J Clin Pharmacol. 2004; 44: 991-1002
        View in Article
        • Elliot S.
        • Pham E.
        • Macdougall I.
        Erythropoietins: A common mechanism of action.
        Experimental Hematology. 2008; 36: 1573-1584
        View in Article

      Article info

      Publication history

      Published online: July 27, 2016
      Accepted: June 10, 2016

      Identification

      DOI: https://doi.org/10.1016/j.clinthera.2016.06.010

      Copyright

      © 2016 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX